Mark B. Juckett, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Mark Juckett joined the Bone Marrow Transplant Program at the University of Wisconsin in December 2000. In conjunction with the other transplant physicians, Dr. Juckett provides inpatient and outpatient care for blood and bone marrow transplant patients, as well as clinical outreach services in Portage, Wisconsin. He has developed or assisted in the development of innovative treatment protocols for use in bone marrow transplant patients. With over 10 years of experience in blood and bone marrow transplantation, his clinical interests include acute leukemia, myelodysplastic syndromes, other hematologic malignancies, hematopoietic stem cell transplantation and immunotherapy of cancer.
UW Health Clinics
Professional Certifications and Education
University of Minnesota
University of Minnesota
University of Louisville School of Medicine, Louisville, KY, 1987
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
Dr. Juckett's current research activities include immunotherapy after hematopoietic stem cell transplantation, non-myeloablative stem cell transplantation, and treatment of myelodysplastic syndromes and acute myelogenous leukemia.
Mattison R Jumonville A Flynn PJ Moreno-Aspitia A Erlichman C LaPlant B Juckett MB .
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2014 Nov 19;:1-6
[PubMed ID: 25329007]
Arai S Arora M Wang T Spellman SR He W Couriel DR Urbano-Ispizua A Cutler CS Bacigalupo AA Battiwalla M Flowers ME Juckett MB Lee SJ Loren AW Klumpp TR Prockup SE Ringdén OT Savani BN Socié G Schultz KR Spitzer T Teshima T Bredeson CN Jacobsohn DA Hayashi RJ Drobyski WR Frangoul HA Akpek G Ho VT Lewis VA Gale RP Koreth J Chao NJ Aljurf MD Cooper BW Laughlin MJ Hsu JW Hematti P Verdonck LF Solh MM Norkin M Reddy V Martino R Gadalla S Goldberg JD McCarthy PL Pérez-Simón JA Khera N Lewis ID Atsuta Y Olsson RF Saber W Waller EK Blaise D Pidala JA Martin PJ Satwani P Bornhäuser M Inamoto Y Weisdorf DJ Horowitz MM Pavletic SZ .
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation - A Report from CIBMTR. Biol Blood Marrow Transplant. 2014 Oct 30;
[PubMed ID: 25445023]
Prebet T Sun Z Figueroa ME Ketterling R Melnick A Greenberg PL Herman J Juckett M Smith MR Malick L Paietta E Czader M Litzow M Gabrilove J Erba HP Gore SD Tallman MS .
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014 Apr 20;32(12):1242-8
[PubMed ID: 24663049]
Hall AC Juckett MB .
The role of vitamin D in hematologic disease and stem cell transplantation. Nutrients. 2013 Jun 18;5(6):2206-21
[PubMed ID: 23778150]
Costanzo ES Juckett MB Coe CL .
Biobehavioral influences on recovery following hematopoietic stem cell transplantation. Brain Behav Immun. 2013 Mar;30 Suppl:S68-74
[PubMed ID: 22820408]
Vanderhoek M Juckett MB Perlman SB Nickles RJ Jeraj R .
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res. 2011 Mar;35(3):310-6
[PubMed ID: 20832860]
Clevidence DE Juckett MB Lucarelli MJ .
Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ. 2009 Dec;108(9):462-5
[PubMed ID: 20131689]
Chang JE Medlin SC Kahl BS Longo WL Williams EC Lionberger J Kim K Kim J Esterberg E Juckett MB .
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307
[PubMed ID: 19052977]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL .
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]
Petrich A Kahl B Bailey H Kim K Turman N Juckett M .
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma. 2008 Jan;49(1):57-61
[PubMed ID: 18203012]
Slattery WR Juckett M Agger WA Radi CA Mitchell T Striker R .
Milkers' nodules complicated by erythema multiforme and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Clin Infect Dis. 2005 Apr 1;40(7):e63-6
[PubMed ID: 15824977]